Evidence map›Paper›PMID 40747784›Full record

ArticleAdvanced healthcare materials2025

Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma.

Shannuo Li, Jiahui Li, Hasan Al Faruque, Paul Shami, Birgit Knoechel, Jens Lohr, Douglas Sborov, Jiyuan Yang, Jindřich Kopeček

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shannuo LiDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.
Jiahui LiDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.
Hasan Al FaruqueDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.
Paul ShamiHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
Birgit KnoechelHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
Jens LohrHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
Douglas SborovHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
Jiyuan YangDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.ORCID 0000-0003-3948-8448
Jindřich KopečekDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.ORCID 0000-0002-4451-6944

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Drug-Free Macromolecular TherapeuticsR01CA246716 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI JINDRICH H. KOPECEK, JIYUAN YANG · 2020 to 2026
$2.1M
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implicationsR01CA249185 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KNOECHEL, BIRGIT · 2021 to 2025
$1.9M
Liquid Biopsy in Myeloma to Inform Outcome and Treatment DecisionsR37CA276044 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jens G Lohr · 2023 to 2026
$1.5M
Huntsman Cancer Institute, University of UtahNCI NIH HHS P30 CA042014NCI NIH HHS R01 CA246716NCI NIH HHS R01 CA249185NCI NIH HHS R37 CA276044NIH
6 · The paper itself

Abstract

Bispecific T-cell engagers show promise in treating multiple myeloma (MM), but challenges remain in adaptability and targeting flexibility. This paper presents a novel T-cell based immunotherapy, Multi-Antigen TCell Hybridizers (MATCH), a modular, self-assembling T-cell engager designed for versatile and patient-specific cancer targeting. MATCH consists of two components: a B-cell-targeting Fab' fragment conjugated to a 25-base morpholino oligonucleotide (Fab'

Indexed as

ImmunotherapyMultiple MyelomaT-LymphocytesAnimalsCell Line, TumorHumansImmunoglobulin Fab FragmentsMicePrecision MedicineImmunoglobulin Fab FragmentsB‐cell maturation antigen (BCMA)drug‐free macromolecular therapeuticsmorpholino oligonucleotidesmultiple myelomaT cell‐redirected immunotherapy

Identifiers

PMID40747784
PMCPMC12616583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.